Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
Holding NYXH?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.39Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jun 10, 2021
|% Change Since: 9.10%
|Next Earnings Date:Apr 09, 2021
Earnings Call Sentiment|Neutral
The earnings call presented a positive outlook with strong clinical trial results, significant regulatory progress, and successful capital raising efforts. However, there are challenges related to increased operational losses, FDA inspection delays, and uncertainties in reimbursement strategies.Company Guidance
During the Nyxoah Q3 2024 earnings call, the company provided significant guidance on various performance metrics and strategic initiatives. Nyxoah achieved a revenue of EUR 1.3 million for the quarter, with an operating loss of EUR 15 million, compared to EUR 11 million in the same period last year, largely due to increased commercial investments in the U.S. The company's cash and financial assets as of September 30, 2024, totaled EUR 71 million, with a monthly cash burn rate of EUR 5.6 million. Notably, they have extended their cash runway until mid-2026, bolstered by a EUR 24.6 million capital raise. The company anticipates FDA approval for Genio in Q1 2025 and has focused on bolstering its U.S. presence and commercialization strategy, expecting a commercial team of about 50 people. Additionally, the DREAM study results showed an AHI response rate of 66.4% on a modified ITT basis, with an ODI responder rate of 71.3%, underscoring Genio's efficacy and safety profile in treating obstructive sleep apnea.Strong DREAM Study Results
The DREAM U.S. pivotal study achieved its efficacy endpoints with a strong safety profile, demonstrating AHI response rates of 63.5% on an ITT basis and 66.4% on a modified ITT basis, with a p-value of 0.002.
Regulatory Progress and Anticipated FDA Approval
The company completed the fourth and final module in its modular PMA submission, anticipating FDA approval in Q1 2025.
Significant Capital Raise
Raised EUR 24.6 million in new capital from a single U.S. healthcare dedicated fund, extending cash runway to mid-2026.
Commercial Expansion in the U.S.
Strengthened U.S. presence with the hiring of key executive roles, and planning a commercial organization of approximately 50 people by the time of launch.
Strong Market Performance in Germany
Achieved a 25% overall market share in Germany only 24 months after launch, serving as a proxy for U.S. adoption trajectory.
---
NYXH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NYXH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $10.00 | $9.64 | -3.60% |
| Aug 06, 2024 | $7.88 | $8.24 | +4.57% |
| May 14, 2024 | $9.58 | $10.27 | +7.20% |
| Mar 05, 2024 | $15.00 | $13.75 | -8.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nyxoah (NYXH) report earnings?
Nyxoah (NYXH) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Nyxoah (NYXH) earnings time?
Nyxoah (NYXH) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NYXH EPS forecast?
NYXH EPS forecast for the fiscal quarter 2024 (Q4) is -0.48.
---